Cellectar shares surge 12.66% premarket as company highlights 2026 strategic initiatives and 2025 clinical/regulatory milestones.

Cellectar Biosciences (NASDAQ: CLRB) surged 12.66% in premarket trading following the announcement of its strategic initiatives for 2026, including a presentation by CEO James Caruso at the 44th Annual JP Morgan Healthcare Conference. The news highlighted key 2025 milestones: FDA Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom's macroglobulinemia (WM), positive Phase 1b data for pediatric high-grade glioma, and $15.2 million in fundraising. Caruso emphasized momentum toward European conditional approval for iopofosine I-131 in 2027 and pipeline validation through clinical trials, positioning the company to advance regulatory pathways and create shareholder value. The premarket rally reflects investor optimism about Cellectar’s progress in targeted radiotherapeutics and its strategic focus on high-impact oncology indications.